New Delhi, Oct. 27 -- Intellia Therapeutics has temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nex-z, a CRISPR-based therapy for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN). The suspension follows a severe safety event involving one participant.

According to the company, a patient in the MAGNITUDE trial who was dosed on September 30 developed Grade 4 liver transaminase elevations and increased total bilirubin, reported on October 24. The incident met the protocol's criteria for pausing the study. The patient has been hospitalized and is receiving treatment while under close monitoring.

"In line with our commitment to patient safety, we have tak...